Patent Grant
11767296
This application is the national phase of International Application No. PCT/CN2019/078006, titled “HETEROARYL COMPOUNDS AS KINASE INHIBITOR”, filed on Mar. 13, 2019, which claims the priority of Chinese Patent Application No. 201810212171.9, filed on Mar. 15, 2018 and Chinese Patent Application No. 201810835038.9, filed on Jul. 26, 2018, filed with China National Intellectual Property Administration, and titled with “HETEROARYL COMPOUNDS AS KINASE INHIBITOR”, and the disclosures of which are hereby incorporated by reference.
The present invention relates to a compound having kinase inhibitory activity and its use in the field of medicine. More specifically, the present invention provides heteroaryl compounds having protein tyrosine kinase activity. The information provided is intended solely to assist the understanding of the reader. None of the information provided nor references cited is admitted to be prior art to the present invention. Each of the references cited is incorporated herein in its entirety and for any purpose.
Protein tyrosine kinase can catalyze a variety of substrate proteins tyrosine residues to phosphorylate, and plays an important role in modulating cell growth, proliferation and differentiation. The aberrant kinase activity is associated with many human diseases, including cancer, autoimmune diseases and inflammatory diseases. As a mediator of cell signaling, protein tyrosine kinase can be a potential target of small molecule kinase inhibitors for modulating cell function, which is used for drug design.
One of the prime aspects of PTK activity is their involvement with growth factor receptors. The growth factor receptors are cell-surface proteins. When bound by a growth factor ligand, growth factor receptors are converted to an active form which interacts with proteins on the inner surface of a cell membrane. This leads to phosphorylation on tyrosine residues of the receptor and other proteins and to the formation inside the cell of complexes with a variety of cytoplasmic signaling molecules that, in turn effect numerous cellular responses, such as cell division (proliferation), cell differentiation, cell growth, and expression of the metabolism of the extracellular microenvironment, etc. For a more complete discussion, see Schiessinger and Ullrich, Neuron, 9:303-391 (1992), which is incorporated by reference, including any drawings, as if fully set forth herein.
The growth factor receptors with PTK activity are known as receptor tyrosine kinase (“RTKs”). They comprise a large family of transmembrane receptors with diverse biological activity. At present, at least 19 distinct subfamilies of RTKs have been identified. An example of these is the subfamily designated the “HER” RTKs, which include EGFR (epithelial growth factor receptor), HER2, HER3 and HER4. These RTKs consist of an extracellular glycosylated ligand binding domain, a transmembrane domain, and an intracellular cytoplasmic catalytic domain that can phosphorylate tyrosine residues on proteins.
Another RTK subfamily consists of insulin receptor (IR), insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor-related receptor (IRR). IR and IGF-1R interact with insulin, IGF-I and IGF-II to form a heterotetramer of two entirely extracellular glycosylated α subunits and two β subunits which cross the cell membrane and which contain the tyrosine kinase domain.
A third RTK subfamily is referred to as the platelet derived growth factor receptor (“PDGFR”) group, which includes PDGFR α, PDGFR ρ, Flt 3, c-kit, and c-fms. These receptors consist of glycosylated extracellular domains composed of variable numbers of immunoglobulin-like loops and an intracellular domain wherein the tyrosine kinase domain is interrupted by unrelated amino acid sequences.
Another group which, because of its similarity to the PDGFR subfamily, is sometimes subsumed into the later group is the fetus liver kinase (“flk”) receptor subfamily. The group is believed to be made up of kinase insert domain-receptor fetal liver kinase-1 (KDR/FLK-1), flk-1R, flk-4 and fins-like tyrosine kinase (flt-1).
A further member of the tyrosine kinase growth factor receptor family is the fibroblast growth factor (“FGF”) receptor subgroup. The group consists of four receptors, FGFR1-4, and seven ligands, FGF1-7. While not yet well defined, it appears that the receptors consist of a glycosylated extracellular domain containing a variable number of immunoglobulin like loops and an intracellular domain in which the tyrosine kinase sequence is interrupted by regions of unrelated amino acid sequences.
Still another member of the tyrosine kinase growth factor receptor family is the vascular endothelial growth factor (“VEGF”) receptor subgroup. VEGF is a dimeric glycoprotein similar to PDGF but has different biological functions and target cells specificity in vivo. In particular, VEGF is presently thought to play an essential role in vasculogenesis and angiogenesis.
Still another member of the tyrosine kinase growth factor receptor group is MET, often referred to as c-Met, also known as human hepatocyte growth factor receptor tyrosine kinase (hHGFR). c-Met is thought to play a role in primary tumor growth and metastasis.
A more complete listing of the known RTK subfamilies is described in Plowman et al., DN&P, 7(6): 334-339 (1994), which is incorporated by reference, including any drawings, as if fully set forth herein.
The colony stimulating factor 1 receptor (CSF-1R), also known as macrophage colony stimulating factor receptor (M-CSFR)) and CD115 (differentiation cluster 115), is a cell surface protein encoded by the CSF-1R gene (also known as c-fms) in the human body. c-fms is a III transmembrane receptor protein tyrosine kinase (receptor protein tyrosinekinases, RPTKs), which regulates the key signal transduction cascade reactions that regulate cell growth and proliferation. The receptor consists of five immunoglobulin (IG) domains, one transmembrane domains, and a separate cytoplasmic kinase domain separated by the kinase inserting part.
c-fms was originally a member of the gene family isolated from the Susan McDonough strain of feline sarcoma viruses. The cellular proto-oncogene FMS (c-fms, cellular feline McDonough sarcoma) codes for the receptor of macrophage Colony-Stimulating Factor (M-CSF). c-fms is crucial for the growth and differentiation of monocyte-macrophage lineage, and upon binding of M-CSF to the extracellular domain of c-fms, the receptor dimerizes and transautophosphorylates cytoplasmic tyrosine residues.
M-CSF, originally described by Robinson and co-workers (Blood. 1969, 33:396-9), is a cytokine that controls the production, differentiation and function of macrophages. M-CSF stimulates the differentiation of progenitor cells into mature monocytes and prolongs the survival of monocytes. Furthermore, M-CSF enhances cytotoxicity; superoxide production, phagocytosis, chemotaxis, and secondary cytokine production of additional factors in monocytes and macrophages. Examples of such additional factors include granulocyte colony-stimulating factor (G-CSF), interleukin-6 (IL-6), and interleukin-8 (IL-8). M-CSF stimulates hematopoiesis, promotes the differentiation and proliferation of osteoclast progenitor cells, and has profound effects on lipid metabolism. Furthermore, M-CSF is important in pregnancy. Physiologically, large amounts of M-CSF are produced in the placenta, and M-CSF is believed to plays an essential role in trophoblast differentiation (Motoyoshi, Int J. Hematol. 1998, 67:109-22). The elevated serum levels of M-CSF in early pregnancy may participate in the immunologic mechanisms responsible for the maintenance of the pregnancy (Flanagan & Lader, Curr Opin Hematol. 1998, 5:181-5).
Related to c-fms and c-kit are two kinds of platelet derived growth factor receptors, a (alpha) (i.e., pdgfra) and β (beta) (pdgfrb) (PDGF). The gene coding for pdgfra is located on chromosome 4q11-q12 in the same region of chromosome 4 as the oncogene coding for c-kit. The genes coding for pdgfra and c-fms appear to have evolved from a common ancestral gene by gene duplication, inasmuch as these two genes are tandemly linked on chromosome 5. They are oriented head-to-tail with the 5-prime exon of the c-fms gene located only 500 bp from the last 3-prime exon of the gene coding for pdgfra. The observation that production of M-CSF, the major macrophage growth factor, is increased in tissues during inflammation points out a role for c-fms in diseases, such as for example inflammatory diseases. More particularly, because elevated levels of M-CSF are found in the disease state, modulation of the activity of c-fms can ameliorate disease associated with increased levels of M-CSF.
The present invention provides compounds with tyrosine kinase inhibitory activity.
The present invention described compounds comprising at least a compound of Formula (I).
Wherein:
In any and all embodiments, substituents may be selected from a subset of the selected items listed. For example, in some implementations, R3 is selected from H or halogen.
In some implementations, R3 is selected from H or halogen; W is selected from phenyl or 5-10 membered heteroaryl, and the hydrogen on the ring may be substituted by one or more R7 groups independently, and the two adjacent R7 can join to form a 5-7 membered ring; and R7 is selected from H, halogen, OH, NO2, CN, O(C1-C3)alkyl, (C1-C5)heteroalkyl, O(C3-C6)cycloalkyl, O(C3-C6) heterocycloalkyl, C1-C5 alkyl, alkenyl, alkynyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, NH2, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2.
In some embodiments, W is selected from phenyl or 5-10 membered heteroaryl, and the hydrogen on the ring may be substituted by one or more R7 groups independently, and one of the substituents must be selected from NH2, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2, and the two adjacent R7 groups can join to form a 5-7 membered ring; In further implementation, W is selected from phenyl, wherein the hydrogens on the ring may be substituted by one or more R7 groups independently, one of the substituents must be selected from NH2, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2, and the two adjacent R7 groups can join to form a 5-7 membered ring.
In some embodiments, W is selected from phenyl or 5-10 membered heteroaryl, and the hydrogen on the ring may be substituted by one or more R7 groups independently, and one of the substituents must be selected from NH2, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2, and the two adjacent R7 groups can join to form a 5-7 membered ring; R3 is selected from phenyl, 5-10 membered heteroaryl, wherein the hydrogens on the ring may be substituted by halogen, OH, NO2, CN, O(C1-C3)alkyl, (C1-C5)heteroalkyl, O(C3-C6)cycloalkyl, O(C3-C6)heterocycloalkyl, C1-C5 alkyl, CH═CH C≡C, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2; and the adjacent substituted groups in R3 can join to form a 5-7 membered ring; In further implementation, wherein W is selected from phenyl or 5-10 membered heteroaryl, and the hydrogen on the ring may be substituted by one or more R7 groups independently, and one of the substituents must be selected from NH2, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2, and the two adjacent R7 groups can join to form a 5-7 membered ring; R3 is selected from phenyl, pyrazolyl, pyridyl, wherein the hydrogens on the ring may be substituted by halogen, CN, O(C1-C3)alkyl, C1-C3alkyl, C3-C6cycloalkyl, (C1-C5)heteroalkyl, C3-C6 heterocycloalkyl, N((C1-C2)alkyl)2, NH(C1-C2)alkyl; and the adjacent substituted groups in R3 can join to form a 5-7 membered ring.
In some embodiments, W is selected from phenyl, wherein the hydrogens on the ring may be substituted by one or more R7 groups independently, one of the substituents must be selected from NH2, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2, and the two adjacent R7 groups can join to form a 5-7 membered ring; R3 is selected from phenyl, 5-10 membered heteroaryl, wherein the hydrogens on the ring may be substituted by halogen. OH, NO2, CN, O(C1-C3)alkyl, (C1-C5)heteroalkyl, O(C3-C6)cycloalkyl, O(C3-C6)heterocycloalkyl, C1-C5 alkyl, CH═CH, C≡C, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2; and the adjacent substituted groups in R3 can join to form a 5-7 membered ring; In further implementation, W is selected from phenyl, wherein the hydrogens on the ring may be substituted by one or more R7 groups independently, one of the substituents must be selected from NH2, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2, and the two adjacent R7 groups can join to form a 5-7 membered ring; R3 is selected from phenyl, pyrazolyl, pyridyl, wherein the hydrogens on the ring may be substituted by halogen, CN, O(C1-C3)alkyl, C1-C3alkyl, C3-C6 cycloalkyl, (C1-C5)heteroalkyl, C3-C6 heterocycloalkyl, N((C1-C2)alkyl)2, NH(C1-C2)alkyl; and the adjacent substituted groups in R3 can join to form a 5-7 membered ring.
In some embodiments, A is selected from N; R3 is selected from H or halogen; W is selected from phenyl or 5-10 membered heteroaryl, and the hydrogen on the ring may be substituted by one or more R7 groups independently, and the two adjacent R7 can join to form 5-7 membered ring; and R7 is selected from H, halogen, OH, NO2, CN, O(C1-C3)alkyl, (C1-C5)heteroalkyl, O(C3-C6)cycloalkyl, O(C3-C6) heterocycloalkyl, C1-C5 alkyl, alkenyl, alkynyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, NH2, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2.
In some embodiments, A is selected from N; W is selected from phenyl, wherein the hydrogens on the ring may be substituted by one or more R7 groups independently, one of the substituents must be selected from NH2, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2, and the two adjacent R7 groups can join to form a 5-7 membered ring; R3 is selected from phenyl, 5-10 membered heteroaryl, wherein the hydrogens on the ring may be substituted by halogen, OH, NO2, CN, O(C1-C3)alkyl, (C1-C5)heteroalkyl, O(C3-C6)cycloalkyl, O(C3-C6)heterocycloalkyl, C1-C5alkyl, CH═CH, C≡C, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2; and the adjacent substituted groups in R3 can join to form a 5-7 membered ring; In further implementation, A is selected from N; W is selected from phenyl, wherein the hydrogens on the ring may be substituted by one or more R7 groups independently, one of the substituents must be selected from NH2, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2, and the two adjacent R7 groups can join to form a 5-7 membered ring; R3 is selected from phenyl, pyrazolyl, pyridyl, wherein the hydrogens on the ring may be substituted by halogen, CN, O(C1-C3)alkyl, C1-C3alkyl, C3-C6cycloalkyl, (C1-C5)heteroalkyl, C3-C6 heterocycloalkyl, N((C1-C2)alkyl)2, NH(C1-C2)alkyl; and the adjacent substituted groups in R3 can join to form a 5-7 membered ring;
A preferred embodiment of the above-listed embodiments has a compound represented by the formula (Ia):
Wherein:
In some implementations of this preferred embodiment, R2 is selected from H; in some further implementations, R2 is selected from H; Z is selected from phenyl or pyridyl, wherein the hydrogens on the ring may be substituted by one or more R4 groups independently, and R4 is selected from halogen, OH, CN, O(C1-C3)alkyl, C1-C3 alkyl;
In some implementations of this preferred embodiment, Z is selected from phenyl or pyridyl, wherein the hydrogens on the ring may be substituted by one or mom R4 groups independently, and R4 is selected from halogen, OH, CN, O(C1-C3)alkyl, C1-C3 alkyl; In some further implementations. Z is selected from phenyl or pyridyl, wherein the hydrogens on the ring may be substituted by one or more R4 groups independently, and R4 is selected from halogen, OH, CN, O(C1-C3)alkyl, C1-C3 alkyl; Q is selected from OC(R5R6), and each R5 and R6 is independently selected from H, C1-C3 alkyl, or R5 and R6 can join to form a 3-6 membered ring; In the further implementation, Z is selected from phenyl or pyridyl, wherein the hydrogens on the ring may be substituted by one or more R4 groups independently, and R4 is selected from halogen, OH, CN, O(C1-C3)alkyl, C1-C3 alkyl; Q is selected from OC(R5R6), one of R5 and R6 is dydrogen, the other is selected from C1-C3 alkyl;
In some embodiments of this preferred embodiment, R2 is selected from H; Z is selected from phenyl or pyridyl, wherein the hydrogens on the ring may be substituted by one or more R4 groups independently, and R4 is selected from halogen, OH, CN, O(C1-C3)alkyl, C1-C3 alkyl. In some further embodiments, R2 is selected from H; Z is selected from phenyl or pyridyl, wherein the hydrogens on the ring may be substituted by one or more R4 groups independently, and R4 is selected from halogen, OH, CN, O(C1-C3)alkyl, C1-C3 alkyl; Q is selected from OC(RR), and each R5 and R6 is independently selected from H, C1-C3 alkyl, or R5 and R6 can join to form a 3-6 membered ring; In a further implementation, R2 is selected from H; Z is selected from phenyl or pyridyl, wherein the hydrogens on the ring may be substituted by one or more R4 groups independently, and R4 is selected from halogen, OH, CN, O(C1-C3)alkyl, C1-C3 alkyl; Q is selected from OC(R5R6), one of R5 and R6 is dydrogen, the other is selected from C1-C3 alkyl:
In some embodiments of this preferred embodiment, X is selected from OCH2, NHCH2, NHC(O), NHS(O)2, C(O)NH, S(O)2NH, NHC(O)NH, NHC(S)NH. In some further embodiments, X is selected from NHC(O), C(O)NH, NHC(O)NH, NHC(O)NH, NHC(S)NH.
In some implementations of this preferred embodiment, Z is selected from phenyl or pyridyl, wherein the hydrogens on the ring may be substituted by one or more R4 groups independently, and R4 is selected from halogen, OH, CN, O(C1-C3)alkyl, C1-C3 alkyl; X is selected from OCH2, NHCH2, NHC(O), NHS(O)2, C(O)NH, S(O)2NH, NHC(O)NH, NHC(S)NH; In some further implementations, Z is selected from phenyl or pyridyl, wherein the hydrogens on the ring may be substituted by one or more R4 groups independently, and R4 is selected from halogen, OH, CN, O(C1-C3)alkyl, C1-C3 alkyl; Q is selected from OC(R5R6), and each R5 and R6 is independently selected from H, C1-C3 alkyl, or R5 and R6 can join to form a 3-6 membered ring; X is selected from OCH2, NHCH2, NHC(O), NHS(O)2, C(O)NH, S(O)2NH, NHC(O)NH, NHC(S)NH; In the further implementation, Z is selected from phenyl or pyridyl, wherein the hydrogens on the ring may be substituted by one or more R4 groups independently, and R4 is selected from halogen, OH, CN, O(C1-C3)alkyl, C1-C3 alkyl; Q is selected from OC(R5R6), one of R5 and R6 is dydrogen, the other is selected from C1-C3 alkyl; X is selected from OCH2, NHCH2, NHC(O), NHS(O)2, C(O)NH, S(O)2NH, NHC(O)NH, NHC(S)NH.
In some embodiments of this preferred embodiment, R2 is selected from H; Z is selected from phenyl or pyridyl, wherein the hydrogens on the ring may be substituted by one or more R4 groups independently, and R4 is selected from halogen, OH, CN, O(C1-C3)alkyl, C1-C3 alkyl; X is selected from NHC(O). C(O)NH, NHC(O)NH, NHC(S)NH. In some further embodiments. R2 is selected from H; Z is selected from phenyl or pyridyl, wherein the hydrogens on the ring may be substituted by one or more R4 groups independently, and R4 is selected from halogen, OH, CN, O(C1-C3)alkyl, C1-C3 alkyl; Q is selected from OC(R5R6), and each R5 and R6 is independently selected from H, C1-C3 alkyl, or R5 and R6 can join to form a 3-6 membered ring; X is selected from NHC(O), C(O)NH, NHC(O)NH, NHC(S)NH. In a further implementation, R2 is selected from H; Z is selected from phenyl or pyridyl, wherein the hydrogens on the ring may be substituted by one or more R4 groups independently, and R4 is selected from halogen, OH, CN, O(C1-C3)alkyl, C1-C3 alkyl; Q is selected from OC(R5R6), one of R5 and R6 is dydrogen, the other is selected from C1-C3 alkyl; X is selected from NHC(O), C(O)NH, NHC(O)NH, NHC(S)NH.
The compound described above is further preferably a compound of the formula (Ib):
Wherein:
In some embodiments, R3 in the formula (Ib) is selected from H, halogen; W is selected from phenyl or 5-10 membered heteroaryl, wherein the hydrogens on the ring may be substituted by one or more R7 groups independently, and the two adjacent R7 groups can join to form a 5-7 membered ring; R7 is selected from halogen, OH, NO2, CN, O(C1-C3)alkyl, (C1-C5) heteroalkyl, O(C3-C6)cycloalkyl, O(C3-C6)heterocycloalkyl, C1-C5 alkyl, C═C, C≡C, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2.
In some embodiments, R3 in the formula (Ib) is selected from phenyl, 5-10 membered heteroaryl, C3-C6 heterocycloalkyl, wherein the hydrogens on the ring may be substituted by halogen, OH, NO2, CN, O(C1-C3)alkyl, (C1-C5)heteroalkyl, O(C3-C6)cycloalkyl, O(C3-C6)heterocycloalkyl, C1-C5 alkyl, C═C, C≡C, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2; W is selected from phenyl or 5-10 membered heteroaryl, wherein the hydrogens on the ring may be substituted by one or more R7 groups independently, and one of the substituted groups should be selected from NH2, N((C1-C2)alkyl)2, NH(C1-C2)alkyl, C(O)(C1-C2)alkyl, C(O)O(C1-C2)alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3)alkyl, wherein n=0, 1 or 2, and the adjacent groups in R7 or W can join to form a 5-7 membered ring; In some further embodiments, R3 is selected from phenyl, pyrazolyl, pyridyl, wherein the hydrogens on the ring may be substituted by halogen, CN, O(C1-C3)alkyl, C1-C3 alkyl, C3-C6 cycloalkyl, (C1-C5)heteroalkyl, C3-C6 heterocycloalkyl, N((C1-C2)alkyl)2, NH(C1-C2)alkyl; and the adjacent substituted groups in R3 can join to form a 5-7 membered ring. In still further embodiments, R3 is selected from pyrazolyl, pyridyl, wherein the hydrogens on the ring may be substituted by halogen. CN, C1-C3 alkyl, C3-C6 cycloalkyl, (C1-C5) heteroalkyl, C3-C6 heterocycloalkyl, and the adjacent substituted groups on R3 can join to form a 5-7 membered ring.
In some embodiments, R3 in the formula (Ib) is selected from phenyl, pyrazolyl, pyridyl, wherein the hydrogens on the ring may be substituted by halogen, CN, O(C1-C3)alkyl, C1-C3 alkyl, C3-C6cycloalkyl, (C1-C3)heteroalkyl, C3-C6 heterocycloalkyl, N((C1-C2)alkyl)2, NH(C1-C2)alkyl; and the adjacent substituted groups in R3 can join to form a 5-7 membered ring; W is selected from phenyl, wherein the hydrogens on the ring is substituted by one or more R7 groups independently, and one of the substituted groups should be selected from N((C1-C2)alkyl)2, C(O)(C1-C2) alkyl, C(O)O(C1-C2) alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3) alkyl, wherein n=0, 1 or 2, and the adjacent substituted groups in W can join to form a 5-7 membered ring. In some further embodiments, R3 is selected from pyrazolyl, pyridyl, wherein the hydrogens on the ring may be substituted by halogen, CN, C1-C3 alkyl, C3-C6 cycloalkyl, (C1-C5) heteroalkyl, C3-C6 heterocycloalkyl, and the adjacent substituted groups on R3 can join to form a 5-7 membered ring; W is selected from phenyl, wherein the hydrogens on the ring is substituted by one or more R7 groups independently, and one of the substituted groups should be selected from N((C1-C2)alkyl)2, C(O)(C1-C2) alkyl, C(O)O(C1-C2) alkyl, P(O)((C1-C2)alkyl)2, SO2 cyclopropyl, S(O)n(C1-C3) alkyl, wherein n=0, 1 or 2, and the adjacent substituted groups in W can join to form a 5-7 membered ring.
More specifically, the preferred compounds of the invention are selected from any one of the following compounds:
The pharmaceutical composition of the present invention contains at least one effective therapeutic amount of a compound of the above formula (I) and at least one pharmaceutically acceptable excipient, adjuvant or carrier.
The pharmaceutical composition of the invention can be applied to pharmaceutical manufacture.
The method of the present invention for treating abnormal cell growth in a mammal comprising administering to the subject a therapeutically effective amount of a compound of the above formula (I) or a pharmaceutical composition thereof, wherein the abnormal cell growth is preferably tumor.
The present invention is for use in the treatment and prevention of CSF-1R kinase mediated melanoma, ovarian cancer, uterine cancer, breast cancer, colon cancer, gastric cancer, liver cancer and non-small cell lung cancer, comprising administering a therapeutically effective amount to a subject Compound of formula (I) or a pharmaceutical composition thereof.
The compounds and pharmaceutical compositions of the present invention are useful for the preparation of a medicament for treating abnormal cell growth in a mammal, wherein abnormal cell growth is preferably tumor.
The compounds and pharmaceutical compositions of the invention are useful in the manufacture of a medicament for the treatment and prevention of CSF-1R kinase mediated tumor.
The compounds and pharmaceutical compositions of the invention are administered in combination with chemotherapeutic agents, radiation, and/or cancer immunotherapy.
Unless otherwise stated, the following terms used in the specification and claims have the meanings discussed below. Variables defined in this section, such as A, R, X, Z and the like, are for reference within this section only, and are not meant to have the save meaning as may be used outside of this definitions section. Further, many of the groups defined herein can be optionally substituted. The listing in this definitions section of typical substituents is exemplary and is not intended to limit the substituents defined elsewhere within this specification and claims.
“Cm-Cn” refers to the carbon atoms contained in m-n.
“Alkyl” refers to a saturated aliphatic hydrocarbon radical or linker including straight chain and branched chain groups of 1 to 20 carbon atoms, preferably 1 to 12 carbon atoms, more preferably 1 to 8 carbon atoms, or 1 to 6 carbon atoms, or 1 to 4 carbon atoms. “Lower alkyl” refers specifically to an alkyl group with 1 to 4 carbon atoms. Examples of alkyl groups include —(CH2)3—, methyl, ethyl, propyl, 2-propyl, n-butyl, iso-butyl, tert-butyl, pentyl, and the like. Alkyl may be substituted or unsubstituted. Typical substituent groups include cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, nitro, silyl, amino and —NRxRy, where Rx and Ry are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl, acetyl, sulfonyl, trifluoromethanesulfonyl and, combined, a five- or six-member heteroalicyclic ring.
“heteroalkyl” include optionally substituted alkyl radicals in which one or more skeletal chain atoms is a heteroatom, e.g., oxygen, nitrogen, sulfur, silicon, phosphorus or combinations thereof. The heteroatom(s) may be placed at any interior position of the heteroalkyl group or at the position at which the heteroalkyl group is attached to the remainder of the molecule. Examples include, but are not limited to, —CH2—O—CH3, —CH2—CH2—O—CH3, —OCH2—, —CH2—NH—CH3, —CH2—CH—NH—CH3, —CH2—N(CH3)—CH3, —NCH2CH2—, —CH2—CH2—NH—CH3, —CH2—CH—N(CH3)—CH3, —CH2—S—CH—CH3, —CH2—CH2—S(O)—CH3, —CH2—CH—S(O)2—CH3. In addition, up to two heteroatoms may be consecutive, such as, by way of example, —CH—NH—OCH3.
“Cycloalkyl” refers to a 3 to 8 member all-carbon monocyclic ring, an all-carbon 5-member/6-member or 6-member/6-member fused bicyclic ring, or a multicyclic fused ring (a “fused” ring system means that each ring in the system shares at least an adjacent carbon atom with each other ring in the system) group wherein one or more of the rings may contain one or more double bonds but none of the rings has a completely conjugated pi-electron system. Examples, without limitation, of cycloalkyl groups are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexadiene, adamantane, cycloheptane, cycloheptatriene, and the like. A cycloalkyl group may be substituted or unsubstituted. Typical substituent groups include alkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, O-carbamyl, N-carbamyl, Camido, N-amido, nitro, amino and —NRxRy, with Rx and Ry as defined above. Illustrative examples of cycloalkyl are derived from, but not limited to, the following:
“Cycloalkylalkyl” or “Alkylcycloalkyl” means an alkyl radical, as defined herein, substituted with a cycloalkyl group. Non-limiting cycloalkylalkyl or alkylcycloalkyl groups include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, methylcyclobutyl and the like.
“Alkenyl” refers to an alkyl group, as defined herein, consisting of at least two carbon atoms and at least one carbon-carbon double bond. Representative examples include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, and the like.
“Aryl” refers to an all-carbon monocyclic or fused-ring polycyclic groups of 6 to 12 carbon atoms having a completely conjugated pi-electron system. Examples, without limitation, of aryl groups are phenyl, naphthalenyl and anthracenyl. The aryl group may be substituted or unsubstituted. Typical substituents include halo, trihalomethyl, alkyl, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, nitro, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, Ocarbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, sulfinyl, sulfonyl, amino and —NRxRy, with Rx and Ry as defined above.
“Heteroaryl” refers to a monocyclic or fused ring group of 5 to 12 ring atoms containing one, two, three or four ring heteroatoms selected from N, O. and S, the remaining ring atoms being C, and, in addition, having a completely conjugated π-electron system. Examples, without limitation, of unsubstituted heteroaryl groups are pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrimidine, quinoline, isoquinoline, purine, tetrazole, triazine, and carbazole. The heteroaryl group may be substituted or unsubstituted. Typical substituents include alkyl, cycloalkyl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, nitro, carbonyl, thiocarbonyl, sulfonamido, C-carboxy, O-carboxy, sulfinyl, sulfonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, amino and —NRxRy with Rx and Ry as defined above.
A pharmaceutically acceptable heteroaryl is one that is sufficiently stable to be attached to a compound of the invention, formulated into a pharmaceutical composition and subsequently administered to a patient in need thereof.
Examples of typical monocyclic heteroaryl groups include, but are not limited to:
“Heteroalicyclic” or “heterocycle” refers to a monocyclic, fused ring group or spiro having in the ring(s) of 3 to 12 ring atoms, in which one or two ring atoms are heteroatoms selected from N, O, and S(O)n (wherein is 0, 1 or 2), the remaining ring atoms being C. The rings may also have one or more double bonds. However, the rings do not have a completely conjugated n-electron system. Examples of suitable saturated heteroalicyclic groups include, but are not limited to:
The heterocycle group is optionally substituted with one or two substituents independently selected from halo, lower alkyl, lower alkyl substituted with carboxy, ester hydroxy, or mono or dialkylamino.
“Hydroxy” refers to an —OH group.
“Alkoxy” refers to both an —O-(alkyl) or an —O-(unsubstituted cycloalkyl) group. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like. The alkyl or cycloalkyl group may be substituted or unsubstituted, and typical substituents include a halogen group and the like. Representative examples include, but are not limited to, trifluoromethoxy, difluoromethoxy, and the like.
“Aryloxy” refers to an —O-aryl or an —O-heteroaryl group, as defined herein. Representative examples include, but are not limited to, phenoxy, pyridinyloxy, furanyloxy, thienyloxy, pyrimidinyloxy, pyrazinyloxy, and the like, and derivatives thereof.
“Mercapto” refers to an —SH group.
“Alkylthio” refers to an —S-(alkyl) or an —S-(unsubstituted cycloalkyl) group. Representative examples include, but are not limited to, methylthio, ethylthio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, and the like.
“Arylthio” refers to an —S-aryl or an —S-heteroaryl group, as defined herein. Representative examples include, but are not limited to, phenylthio, pyridinylthio, furanylthio, thienylthio, pyrimidinylthio, and the like and derivatives thereof.
“Acyl” or “carbonyl” refers to a —C(O)R″ group, where R″ is selected from the group consisting of hydrogen, lower alkyl, trihalomethyl, unsubstituted cycloalkyl, aryl optionally substituted with one or more, preferably one, two, or three substituents selected from the group consisting of lower alkyl, trihalomethyl, lower alkoxy, halo and —NRxRy groups, heteroaryl (bonded through a ring carbon) optionally substituted with one or more, preferably one, two, or three substitutents selected from the group consisting of lower alkyl, trihaloalkyl, lower alkoxy, halo and —NRxRy groups and heteroalicyclic (bonded through a ring carbon) optionally substituted with one or more, preferably one, two, or three substituents selected from the group consisting of lower alkyl, trihaloalkyl, lower alkoxy, halo and —NRxRy groups. Representative acyl groups include, but are not limited to, acetyl, trifluoroacetyl, benzoyl, and the like.
“Aldehyde” refers to an acyl group in which R″ is hydrogen.
“Thioacyl” or “thiocarbonyl” refers to a —C(S)R″ group, with R″ as defined above.
A “thiocarbonyl” group refers to a —C(S)R″ group, with R″ as defined above.
A “C-carboxy” group refers to a —C(O)OR″ group, with R″ as defined above.
An “O-carboxy” group refers to a —OC(O)R″ group, with R″ as defined above.
“Ester” refers to a —C(O)OR″ group with R″ as defined herein except that R″ cannot be hydrogen.
“Acetyl” group refers to a —C(O)CH3 group.
“Halo” group refers to fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.
“Trihalomethyl” group refers to a methyl group having three halo substituents, such as a trifluoromethyl group.
“Cyano” refers to a —C≡N group.
A “sulfinyl” group refers to a —S(O)R″ group wherein, in addition to being as defined above, R″ may also be a hydroxy group.
A “sulfonyl” group refers to a —S(O)2R″ group wherein, in addition to being as defined above, R″ may also be a hydroxy group.
A “Phosphonoyl” group refers to a —P(O)RxRy group, wherein Rx and Ry is selected from alkyl or alkoxy.
“S-sulfonamido” refers to a —S(O)2NRxRy group, with Rx and Ry as defined above.
“N-sulfonamido” refers to a —NRxS(O)2Ry group, with Rx and Ry as defined above.
“O-carbamyl” group refers to a —OC(O)NRxRy group with Rx and Ry as defined above.
“N-carbamyl” refers to an RyOC(O)NRx— group, with Rx and Ry as defined above.
“O-thiocarbamyl” refers to a —OC(S)NRxRy group with Rx and Ry as defined above.
“N-thiocarbamyl” refers to a RyOC(S)NRx— group, with Ry and Rx as defined above.
“Amino” refers to an —NRxRy group, wherein Rx and Ry are both hydrogen.
“C-amido” refers to a —C(O)NRxRy group with Rx and Ry as defined above.
“N-amido” refers to a RxC(O)NRy group, with Rx and Ry as defined above.
“-amido-” refers to a —C(O)NRy— group, with Rx and Ry as defined above.
“Nitro” refers to a —NO2 group.
“imine” refers to a —N═C— group.
“Haloalkyl” means an alkyl, preferably lower alkyl, that is substituted with one or more same or different halo atoms, e.g., —CH2Cl, —CF3, —CH2CF3, —CH2CCl3, and the like.
“Hydroxyalkyl” means an alkyl, preferably lower alkyl, that is substituted with one, two, or three hydroxy groups; e.g., hydroxymethyl, 1 or 2-hydroxyethyl. 1,2-, 1,3-, or 2,3-dihydroxypropyl, and the like.
“Aralkyl” means alkyl, preferably lower alkyl, that is substituted with an aryl group as defined above; e.g., —CH2phenyl, —(CH2)2phenyl, —(CH2)3phenyl, CH3CH(CH3)CH2phenyl, and the like and derivatives thereof.
“Heteroaralkyl” group means alkyl, preferably lower alkyl, that is substituted with a heteroaryl group; e.g., —CH2pyridinyl, —(CH2)2pyrimidinyl, —(CH2)3imidazolyl, and the like, and derivatives thereof.
“Monoalkylamino” means a radical —NHR where R is an alkyl or unsubstituted cycloalkyl group; e.g., methylamino. (1-methylethyl)amino, cyclohexylamino, and the like.
“Dialkylamino” means a radical —NRR where each R is independently an alkyl or unsubstituted cycloalkyl group; dimethylamino, diethylamino, (1-methylethyl)-ethylamino, cyclohexylmethylamino, cyclopentylmethylamino, and the like.
The term “heteroatom” refers to an atom other than carbon or hydrogen. Heteroatoms are typically independently selected from among oxygen, sulfur, nitrogen, silicon and phosphorus, but are not limited to these atoms. In embodiments in which two or more heteroatoms are present, the two or more heteroatoms can all be the same as one another, or some or all of the two or more heteroatoms can each be different from the others.
The term “optionally substituted” or “substituted” means that the referenced group may be substituted with one or more additional group(s) individually and independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arvisulfone, cyano, halo, acyl, nitro, haloalkyl, fluoroalkyl, amino, including mono- and di-substituted amino groups, and the protected derivatives thereof.
“Optional” or “optionally” means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, “heterocycle group optionally substituted with an alkyl group” means that the alkyl may but need not be present, and the description includes situations where the heterocycle group is substituted with an alkyl group and situations where the heterocycle group is not substituted with the alkyl group.
The term “acceptable” or “pharmaceutically acceptable”, with respect to a formulation, composition or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated or does not abrogate the biological activity or properties of the compound, and is relatively nontoxic.
“Therapeutically effective amount” refers to the amount of a compound that, when administered to a subject for treating a disease, or at least one of the clinical symptoms of a disease or disorder, is sufficient to affect such treatment for the disease, disorder, or symptom. The “therapeutically effective amount” can vary depending on the compound, the disease, disorder, and/or symptoms of the disease or disorder, severity of the disease, disorder, and/or symptoms of the disease or disorder, the age of the subject to be treated, and/or the weight of the subject to be treated. An appropriate amount in any given instance can be readily apparent to those skilled in the art or capable of determination by routine experimentation.
As used herein, the term “pharmaceutically acceptable salt” refers to those salts which retain the biological effectiveness and properties of the parent compound. Such salts include:
As used herein, when any variable occurs more than one time in a chemical formula, its definition on each occurrence is independent of its definition at every other occurrence. The compounds of the present disclosure may contain one or more chiral centers and/or double bonds and therefore, may exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers), enantiomers or diastereomers. Accordingly, any chemical structures within the scope of the specification depicted, in whole or in part, with a relative configuration encompass all possible enantiomers and stereoisomers of the illustrated compounds including the stereoisomerically pure form (e.g., geometrically pure, enantiomerically pure or diastereomerically pure) and enantiomeric and stereoisomeric mixtures. Enantiomeric and stereoisomeric mixtures can be resolved into the component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to the skilled artisan. Compounds of Formula I include, but are not limited to optical isomers of compounds of Formula I, racemates, and other mixtures thereof. In those situations, the single enantiomers or diastereomers, i.e., optically active forms, can be obtained by asymmetric synthesis or by resolution of the racemates. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high-pressure liquid chromatography (HPLC) column. In addition, compounds of Formula I include Z- and E-forms (or cis- and trans-forms) of compounds with double bonds. Where compounds of Formula I exist in various tautomeric forms, chemical entities of the present invention include all tautomeric forms of the compound.
Compounds of the present disclosure include, but are not limited to compounds of Formula I, and all pharmaceutically acceptable forms thereof. Pharmaceutically acceptable forms of the compounds recited herein include pharmaceutically acceptable salts, solvates, crystal forms (including polymorphs and clathrates), chelates, non-covalent complexes, prodrugs, and mixtures thereof. In certain embodiments, the compounds described herein are in the form of pharmaceutically acceptable salts. As used henceforth, the term “compound” encompasses not only the compound itself, but also a pharmaceutically acceptable salt thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing.
As noted above, prodrugs also fall within the scope of chemical entities, for example, ester or amide derivatives of the compounds of Formula I. The term “prodrugs” includes any compounds that become compounds of Formula I when administered to a patient, e.g., upon metabolic processing of the prodrug. Examples of prodrugs include, but are not limited to, acetate, formate, and benzoate and like derivatives of functional groups (such as alcohol or amine groups) in the compounds of Formula I.
The present invention compounds can be in the form of composition by oral, inhalation, rectal or parenteral administration administered to patients in need of such treatment. For oral administration, it can be prepared into a solid dosage form such as tablets, powders, granules, capsules, etc., or a liquid dosage form such as aqueous agents, oil-based suspension, syrup, ect. For parenteral administration, the compound/pharmaceutical composition is a solution for injection, an aqueous agent, or an oil-based suspension. Preferably, the dosage form is tablets, coated tablets, capsules, suppositories, nasal sprays and injections, and more preferably, is a oral dosage.
The dosage forms of the compound and pharmaceutically composition disclosed in the invention can be prepared by the conventional methods in pharmaceutical industry. For example, the active ingredient is mixed with one or more excipients, and then formed into the desired dosage form.
The present invention is further exemplified, but not limited, by the following examples that illustrate the preparation of compounds of Formula (I) of the present invention.
The following examples are only used to disclose the preferred embodiments of the present invention, to help technicians in the art understand well, but are not used to limit the spirit and scope of the present invention. In the examples of the present invention, the approach or methods or the like is conventional in the art without specification. The compounds of the present invention can be prepared through, but not limited to, one or more of the following general reaction scheme:
General Experimental Procedures:
To the flask was added 9 (57 mg, 0.2 mmol), R—COOH (1.2 eq, 0.24 mmol), EDCI (58 mg, 0.3 mmol), DMAP (5 mg, 0.04 mmol) in DCM (5 mL) successively, followed by DIPEA (77 mg, 0.6 mmol) with stirring. The resulting mixture was stirred at room temperature for overnight, and purified by column chromatography to give product.
To the dried three-necked flask was added R-methyl-CBS-oxazaborolidine (0.2 eq), BMS (10 M, 2.0 eq) under nitrogen atmosphere. The resulting mixture was diluted with DCM, and stir at 25° C. for 30 min. Then cooled to −30° C., (3-acetylphenyl)tert-butyl carbamate in DCM was added dropwise over 30 min. The mixture was continued to stir for 3 h at −30° C. TLC was used to monitor the reaction. After the reaction was completed, it was quenched by adding MeOH over 30 min. The resulting mixture was stirred at 80° C. for 1 h, then concentrated in vacuo, purified by column chromatography (PE/EA=3:1) and dried in vacuo to give the desired product as colorless oil. LC-MS[M+Na]-m/z: 260.
Similar procedure to the example 3 was followed to arrive at the title compound, with LC-MS[M+H]-m/z 334.
Similar procedure to steps 1 and 3 of the example 18 was followed to arrive at compound 253 with LC-MS[M+H]-m/z 369.
Similar procedure to step 3 of the example 12 was followed to arrive at compound 254 with LC-MS[M+H]-m/z 402.
Similar procedure to step 3 of the example 18 was followed to arrive at compound 255 with LC-MS[M+H]-m/z 388.
Similar procedure to the example 18 was followed to arrive at compounds 256-258.
Synthesis of compounds 273-276 is similar to that of 272.
The obtained oil (500 mg, 1.5 mmol) was redissolved in methanol (20 mL), and then it was added 10% Pd/C (50 mg). The resulting mixture was stirred at room temperature under a hydrogen atmosphere for overnight, filtrated and concentrated. The residue was purified by column chromatography (PE/EA=2:1) to give yellow solid (21 mg, 9%).
Similar procedure to example 3 was followed.
Similar procedure to the step 3 of example 26 was followed. LC-MS[M+H]-m/z: 408.
Synthesis of compound 287 is similar to that of Example 28, with the LC-MS[M+H]-m/z 422.
Synthesis of compound 288 is similar to that of Example 28, with the LC-MS[M+H]-m/z 436.
The synthesis of intermediate 292 is referred to paper [Meyers M J, Pelc M, Kamtekar S, et al. [J]. Bioorganic & Medicinal Chemistry Letters, 2010, 20(5):1543-1547.]
Similar procedure to example 31 was followed to arrive at compound 297, with the LC-MS[M+H]-m/z 396.
Similar procedure to example 13 was followed to arrive at compound 298, with the LC-MS[M+H]-m/z 382.
Similar procedure to example 17 was followed to arrive at compound 299, with the LC-MS[M+H]-m/z 425.
Similar procedure to example 31 was followed to arrive at compound 300, with the LC-MS[M+H]-m/z 383.
Similar procedure to example 31 was followed to arrive at compound 301, with the LC-MS[M+H]-m/z 392.
Similar procedure to example 5 was followed to arrive at compound 315, with the LC-MS[M+H]-m/z 388.
Similar procedure to example 5 was followed to arrive at compound 316, with the LC-MS[M+H]-m/z 404.
Similar procedure to example 5 was followed to arrive at compound 317, with the LC-MS[M+H]-m/z 384.
Similar procedure to example 5 was followed to arrive at compound 318, with the LC-MS[M+H]-m/z 416.
Similar procedure to example 5 was followed to arrive at compound 319, with the LC-MS[M+H]-m/z 402.
Similar procedure to example 5 was followed to arrive at compound 320, with the LC-MS[M+H]-m/z 402.
To a stirred solution of 165 (132 mg, 0.5 mmol) in acetone (2 mL) was added p-Tolyl isocyanate (80 mg, 0.6 mmol). The mixture was stirred at room temperature for 18 h. When the reaction was completed, the insolubles was filtered off, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to give the desired product as white solid. LC-MS[M+H]-m/z 397.
Similar procedure to example 46 was followed to arrive at compound 329, with the LC-MS[M+H]-m/z 397.
The reaction route of compounds 330-347 was as follows:
Compound 180 (100 mg, 0.22 mmol) was added to a 25 mL round bottom flask, then ethanol (10 mL) and hydrogen peroxide (30%, 2 mL) were added. The resulting mixture was stirred for overnight at room temperature. Brine was added and the mixture was extracted with DCM. The combined organic layers were dried, and concentrated in vacuo. The residue was purified by column chromatography (DCM:MeOH=40:1) to give the desired product as white solid. LC-MS[M+H]-m/z: 476.
1. Reagent Preparing
5×Substrate-TK and ATP Solution
The reaction concentration of Substrate-TK and ATP are shown in table 15.
Substrate-TK and ATP were diluted to 5 times of the reaction concentration by 1×Kinase Buffer.
5×Enzyme Solution
The reaction concentration of CSF1R enzyme is shown in table 15.
CSF1R enzyme was diluted to 5×enzyme solution by 1×kinase buffer.
4×Sa-XL665 Solution
The reaction concentration of Sa-XL665 is shown in table 15.
Sa-XL665 was diluted to 4×Sa-XL665 solution by Detection Buffer.
100×TK-Ab-Cryptate Solution
TK-Ab-Cryptate was diluted to 100×TK-Ab-Cryptate solution by Detection Buffer.
2. Experimental Procedure
After all reagents had been prepared according to the above method, except enzymes, the sample was added after equilibrium to room temperature.
3. Data Analysis
Emission Ratio (ER)=665 nm Emission signal/615 nm Emission signal
Inhibitory rate=(ERpositive−ERsample)/(ERpositive−ERnegative)*100%
Using Graphpad Prism 5 and log (inhibitor) vs. normalized response to fit IC50 curve and calculate IC50 value.
The IC50 data of the compounds prepared in Representative Examples 3-52 are as follows (Table 18):
1. Experimental Materials
1.1 Cell Line
Mouse Myelogenous Leukemia Cells (NFS-60)
1.2 Compounds
Using DMSO to dissolve, and the required concentration was prepared with full culture medium without factors.
1.3 Main Reagents
Medium: RPMI Medium 1640, Gibco, No. 31800-022
Fetal Bovine Serum: PANSera. ES, No. 2602-P130707
Penicillin-streptomycin: TRANS
Trypsin: Gibco, No. 25300-062
PBS: Hyclone, No. SH30258.01
Mouse M-CSF/CSF-1 Protein: Sino Biological Inc, No. 51112-MNAH
M-CSF: Qilu Pharmaceutical co., Ltd.
2. Experimental Method
The logarithmic growth phase of NFS-60 cells (1640+10% FBS+40 ng/ml M-CSF+1% Penicillin-streptomycin) were centrifuged (1000 r/min) and cultured in a factor-free medium at 37° C., 5% CO2 for 24 hours. Centrifugating (1000 r/min), the culture medium was replaced by new culture medium including 40 ng/mL factors, and inoculated on 96-well plate by 2*104 cells/mL, 100 μL/hole. After 16 hours, the tested compounds were added 10 μL/hole, 3 duplicate holes per compound, 37° C., 5% CO2, continue to cultured for 72 h. Then 10 μL CCK reagent was added to each hole. After incubation for 4 hours, the absorbance of each hole was measured at 450 nm wavelength.
According to Formula:
Inhibitory rate (%)=(1-OD value of test pore/OD value of solvent control pore)×100%
3. Experimental Results
The experimental results of the inhibition of NFS-60 cell proliferation by the compounds prepared in Example 3-52, 0.5 uM, are shown in the following table:
In this study. MC-38 cell lines were inoculated in C57 mice
Experimental animal: C57 mice, male, 5-6 weeks old (18-22 g)
Cell Lines: MC38
Inoculation: 2×106/0.1 mL, Matrigel is added in 3:1 ratio
PD1: InVivoMAb anti-mouse PD-1 (CD279). BioXCell
Group: On day 4 after inoculating, all the mice were divided into 13 groups, respectively model group, the anti-PD1 2 mg/kg group, anti-PD110 mg/kg group, testing compounds alone, and the tested compound combine with anti-PD1 10 mg/kg. Compounds were intragastrically administered daily at a dose of 30 mg/kg and anti-PD1 was intraperitoneally injected once every 3 days. The drug was administered continuously for 2 weeks. In model group, 80% glycerol+20% CMC-Na was given daily.
Results: The experimental results of anti-PD1 combined with the compounds prepared in the representative example 3-52 on the inhibition of tumor size of MC-38 transplanted tumors are as follows:
Although the present invention has been described in considerable detail with reference to certain preferred versions thereof, other versions are possible. Therefore, the spirit and scope of the present invention should not be limited to the description of the preferred versions described herein. All features disclosed in the specification, including the abstract and drawings, and all the steps in any method or process disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. Each feature disclosed in the specification, including abstract and drawings, can be replaced by alternative features serving the same, equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features. Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in the present application is herein incorporated by reference in its entirety.
| Number | Date | Country | Kind |
|---|---|---|---|
| 201810212171.9 | Mar 2018 | CN | national |
| 201810835038.9 | Jul 2018 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2019/078006 | 3/13/2019 | WO |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2019/174601 | 9/19/2019 | WO | A |
| Number | Date | Country |
|---|---|---|
| 2004004720 | Jan 2004 | WO |
| 2004004720 | Jan 2004 | WO |
| 2004076412 | Sep 2004 | WO |
| 2005002673 | Jan 2005 | WO |
| 2005002673 | Jan 2005 | WO |
| Entry |
|---|
| International Search Report for PCT/CN2019/078006 dated Jun. 13, 2019, ISA/CN. |
| W. A. Robinson, et al. Stimulation of Bone Marrow Colony Growth In Vitro by Human Urine, Blood, vol. 33, No. 3, pp. 396-399, Mar. 1969. |
| Adrienne M. Flanagan, MD, et al. Update on the biologic effects of macrophage colony-stimulating factor, Curr Opin Hematol. 1998, 5:181-5. |
| J. Schiessinger, et al. Growth Factor signaling by Receptor Tyrosine Kinases, Neuron, vol. 9, 383-391, Sep. 1992. |
| Number | Date | Country | |
|---|---|---|---|
| 20220380312 A1 | Dec 2022 | US |
